Al­pha­bet’s Cal­i­co inks $25M li­cens­ing deal for Mab­well’s IL-11 pro­grams

Longevi­ty biotech Cal­i­co is spend­ing $25 mil­lion in cash to li­cense ther­a­peu­tic can­di­dates tar­get­ing the in­ter­leukin-11 pro­tein from Chi­na’s Mab­well.

Cal­i­co will get ex­clu­sive glob­al …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER